Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax
Fen Zhu(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Liam Hackett(Dana-Farber Cancer Institute), Mary C. Collins(Dana-Farber Cancer Institute), James D. Griffin(Harvard University), Stephen Jun Fei Chong(Harvard University), Jennifer L. Crombie(Dana-Farber Cancer Institute), Wei Ni(Dana-Farber Cancer Institute), Nguyet-Minh Hoang(University of Wisconsin Carbone Cancer Center), Lixin Rui(University of Wisconsin Carbone Cancer Center), Swati Garg(Dana-Farber Cancer Institute)
Cited by 14
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752